Fahim Rahim, MD
Nephrology · Chubbuck, IDNPI 1164579736
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $450 of the $524 with a category attached, or 85.9%. 6 manufacturers reported payments, led by AstraZeneca at 48.1% of the total. Reporting peaked in 2024 at $230 and has fallen 83.5% since, to $38 in 2025.
Across 16 payments — averaging $32.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$252
- Amgen$102
- Otsuka America Pharmaceutical, Inc.$79
- Vifor Pharma, Inc.$50
- Novartis$28
- Travere Therapeutics, Inc.$13
What the payments were for
- Food & beverage$45086%
- Education$7414%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $252 |
| Amgen | 5 | $102 |
| Otsuka America Pharmaceutical, Inc. | 2 | $79 |
| Vifor Pharma, Inc. | 2 | $50 |
| Novartis | 1 | $28 |
| Travere Therapeutics, Inc. | 3 | $13 |
How this compares
$524 in reported general payments places this provider in the 65th percentile of 30 nephrology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cinacalcet Hcl | 14 | $8,433 |
| Sevelamer Carbonate | 38 | $6,856 |
| Gentamicin Sulfate | 15 | $882 |
| Calcitriol | 29 | $469 |
| Hydralazine Hcl | 26 | $329 |
| Nifedipine ErNifedipine | 13 | $296 |
| Carvedilol | 25 | $295 |
| Midodrine Hcl | 11 | $215 |
| Amlodipine Besylate | 19 | $193 |
| Furosemide | 25 | $191 |
| Bupropion XlBupropion Hcl | 17 | $183 |
| Metoprolol Succinate | 23 | $174 |
| Torsemide | 11 | $127 |
| Allopurinol | 20 | $101 |
| Losartan Potassium | 12 | $93 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Chubbuck
- Naeem RahimChubbuck$696
- Michael HaderlieChubbuck$347
- Arnold SilvaMeridian$626K
- Liang WuMeridian$386K
- Mary DittrichMeridian$7K
- Shaun JoshiHayden$5K
- Heidi JoistNampa$4K
- Kevin MitchellMeridian$679
- Ajith KumarLewiston$672
- Sherwin FosterHayden$657
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.